MorphoSys as a partner

You are here

MorphoSys has a proven track record of successful alliances including research and development agreements with a number of leading pharmaceutical and biotechnology companies.

Strengthening our development portfolio

Backed by a strong financial position with the mandate to invest in drug development, we are striving to build one of the most valuable pipelines of innovative therapies in the industry. In line with this strategic goal, our partnering activities center on broadening and advancing our development portfolio at different stages of the value chain. We believe trustful and committed partnerships are at the center of every successful program.

MorphoSys has a proven track record of successful alliances including research and development agreements with a number of leading pharmaceutical and biotechnology companies.

Partnerships on clinical and late preclinical stage compounds

MorphoSys is actively looking to in-license compounds in late preclinical or clinical stages, primarily in our core areas: cancer and autoimmune diseases. While MorphoSys’ development expertise is in biologics, we also consider small molecules with a data package that enables IND submission in the near future for in-licensing.

MorphoSys is the ideal partner to quickly advance such compounds to the market and provides a high level of commitment and attention to each single partner and program, as exemplified by the in-licensing of the Fc-enhanced compound tafasitamab (MOR208) from Xencor at IND stage: thanks to MorphoSys dedication and innovative trial design, tafasitamab was approved in the US in July 2020 for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). 

Partnerships on discovery stage compounds, targets and technologies

MorphoSys’ success is deeply rooted in the appreciation of science. We have entered various collaborations with pharmaceutical companies, biotechs and academics to bring in and further develop novel targets, differentiated technologies and promising compounds.

Our ability to turn an in-licensed target into a valuable commercial opportunity for its academic collaborator and its shareholders is exemplified by the otilimab (MOR103) program. Starting from an exclusive license and collaboration agreement with Melbourne University around the target GM-CSF, the program was advanced by MorphoSys into phase 2 clinical development. Based on clinical proof-of-concept data, MorphoSys secured GlaxoSmithKline as a partner to further develop and bring the compound to the market globally.

Various biopharmaceutical companies engaged in even more comprehensive alliances with MorphoSys that typically included joint target validation as well co-development of the resulting drug programs.